THE USE OF RILPIVIRINE/TENOFOVIR/EMTRICITABINE IN HIV-INFECTED PREGNANT WOMEN, ITS EFFECT ON FETAL DEVELOPMENT, PERINATAL TRANSMISSION OF HIV. ANALYSIS OF PHYSICAL AND PSYCHOMOTOR DEVELOPMENT OF CHILDREN 0-2 YEARS OLD

Abstract

The data of medical records of 43 HIV-infected pregnant women and 46 children analyzed for the period from 2017 to 2022. The average age of the women was 33 years (33.6 ± 0.89). Many women (86.0%) had sexual transmission of HIV. The duration of HIV infection in more than half cases (51.1%) was more than 6 years. HIV/HCV co-infection diagnosed in 27.9% of women. 29 HIV-infected women received rilpivirine/ tenofovir/emtricitabine before pregnancy. 14 patients received ART regimens, including 2NRTIs and NNRTIs or Pis, and were switched to rilpivirine/tenofovir/emtricitabine during pregnancy. During pregnancy, CD4+ cells increased from 632.2 ± 42.6) cells/mm³ before pregnancy to 702.1 ± 39.7 cells/mm³ after delivery. HIV RNA levels before pregnancy averaged 795.3 ± 468.1 copies/mL and decreased to undetectable during pregnancy and after delivery. There were no cases of the mother-to-child transmission of HIV. The average birth weight of newborns was 3.350 grams (1.300–4.200), and the average height was 53 cm (45–56). During the observation period, the physical and psychomotor development of children corresponded to age norms.